Zura Bio Ltd financial data

Symbol
ZURA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4225 Executive Square, Suite 600, La Jolla, CA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
JATT Acquisition Corp (to 3/21/2023)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 959 % +64.5%
Debt-to-equity 13.8 % -56%
Return On Equity -40 % +62.9%
Return On Assets -32.3 % +51.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.4M shares +56.8%
Common Stock, Shares, Outstanding 65.3M shares +49.8%
Entity Public Float 206M USD -42.3%
Common Stock, Value, Issued 7K USD +75%
Weighted Average Number of Shares Outstanding, Basic 75.1M shares +127%
Weighted Average Number of Shares Outstanding, Diluted 75.1M shares +127%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.4M USD -44.5%
General and Administrative Expense 30.8M USD +65.2%
Operating Income (Loss) -55.2M USD +11.9%
Nonoperating Income (Expense) 2.79M USD +34.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -52.4M USD +13.5%
Net Income (Loss) Attributable to Parent -52.4M USD +13.2%
Earnings Per Share, Basic -0.6 USD/shares +71.3%
Earnings Per Share, Diluted -0.6 USD/shares +71.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 176M USD +76.8%
Assets, Current 179M USD +77.3%
Property, Plant and Equipment, Net 91K USD
Other Assets, Noncurrent 698K USD
Assets 180M USD +78%
Accounts Payable, Current 733K USD -73.3%
Liabilities, Current 19.5M USD -3.88%
Liabilities 19.5M USD -8.35%
Retained Earnings (Accumulated Deficit) -156M USD -50.6%
Stockholders' Equity Attributable to Parent 147M USD +147%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 148M USD +144%
Liabilities and Equity 180M USD +78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.98M USD -53%
Net Cash Provided by (Used in) Financing Activities 45.7M USD +357%
Net Cash Provided by (Used in) Investing Activities -5.01M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.3M shares +49.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 176M USD +76.8%
Deferred Tax Assets, Valuation Allowance 25.7M USD +43.4%
Deferred Tax Assets, Gross 25.7M USD +43.4%
Payments to Acquire Property, Plant, and Equipment 7K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.01M USD -13.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 303M USD +85.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 16.8M USD +74%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%